Lineage Cell Therapeutics, Inc. (LCTX) is a clinical-stage biotechnology company headquartered in Carlsbad, California. The firm develops novel cell therapies for unmet medical needs. One of the unique features of Lineage is its extensive capabilities in the area of cell therapy and regenerative medicine.
The company’s core trans differentiation technology involves inducing pluripotent stem cells to become specialized cell types for specific applications in a wide range of medical conditions. This disruptive approach in cell therapy is designed to replace damaged or degenerated cells to manufacture life-transforming therapies.
Lineage Cell Therapeutics is currently advancing three clinical-stage programs, including OpRegen®, a retinal pigment epithelium transplant therapy for dry AMD—a leading cause of blindness; OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, currently in a Phase 1 clinical trial for non-small cell lung cancer.
The Company is a pioneer in creating an array of cell therapy platforms, which have the potential to address serious and underserved medical conditions, impacting millions of people globally. For instance, the ongoing trials of OpRegen represent an important advancement for dry AMD, an ailment that affects millions of older people worldwide.
The work at Lineage is driven by the belief that cell therapy will be one of the most powerful approaches in the toolbox of future medicine, enabling doctors to halt or even reverse the damages caused by a variety of debilitating diseases and injuries.
Lineage Cell Therapeutics has a seasoned team of professionals who operate with the highest degree of integrity, quality, and commitment. The shared goal is to unlock the power of stem cells to improve the health and lives of people around the world.
While the road to creating novel cell therapies is complex without guarantee of success, Lineage continues to innovate, invest in research and development and navigate the rigorous scientific and regulatory process.
However, its potential impact on medicine is truly groundbreaking. Injecting healthy, functional cells into patients to replace or rescue affected cells could provide effective long-term, and possibly curative, treatments for a wide range of serious illnesses. This possibility has led to high interest in the future of Lineage Cell Therapeutics, as it takes on the challenges ahead while working towards creating a paradigm shift in treating serious medical ailments.